Many and multiple myeloma(s)

Leukemia

Volumn 17, Issue 10, 2003, Pages 1943-1944

  Fonseca, R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN P53;

CANCER CLASSIFICATION; CANCER SURVIVAL; CARCINOGENESIS; CELL MATURATION; CELL NUCLEUS; CELL PROLIFERATION; CELL STRUCTURE; CHROMOSOME 13; CHROMOSOME 17; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 4; CLONAL VARIATION; CYTOGENETICS; CYTOPLASM; DIPLOIDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; HUMAN; KARYOTYPING; LYMPHOBLAST; LYMPHOCYTE; MEDICAL DECISION MAKING; METAPHASE; MITOSIS; MULTIPLE MYELOMA; NOTE; PATIENT MONITORING; PHENOMENOLOGY; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; CELL DIVISION; CHROMOSOME 11; CHROMOSOME 14; CHROMOSOME MAP; GENE TRANSLOCATION; GENETICS; PATHOLOGY; PLASMACYTOMA;

CELL DIVISION; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; HUMANS; METAPHASE; MULTIPLE MYELOMA; PLASMACYTOMA; TRANSLOCATION, GENETIC;

EID: 0142244332     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403090     Document Type: Note

References (24)

1. Garand R, Avet-Loiseau H, Accard F, Moreau P, Harousseau J, Bataille R. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmocytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003; 17: 2032-2035.
2. Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985; 66: 380-390.
3. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995; 82: 41-49.
4. Cahill DP, Lengauer C, Yu J, Riggins JK, Willson SD, Markowitz K et al. Mutations of mitotic checkpoint genes in human cancers. Nature 1998; 392: 300-303.
5. Rajkumar SV, Fonseca R, Dewald GW, Therneau TM, Lacy MQ, Kyle RA et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999; 113: 73-77.
6. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-4010.
7. Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002; 118: 1041-1047.
8. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98: 2229-2238.
9. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002; 99: 2185-2191.
10. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579-1583.
11. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569-4575.
12. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250-4256.
13. Fonseca R, Harrington D, Oken M, Dewald G, Bailey R, Van Wier S et al. Biologic and prognostic significance of interphase FISH detection of chromosome 13 abnormalities (Δ13) in multiple myeloma: An Eastern Cooperative Oncology Group (ECOG) Study. Cancer Res 2002; 62: 715-720.
14. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Geneviève F, Zandecki M et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta-2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-1571.
15. Drach J, Ackermann J, Fritz E, Kromer E, Schuster R, Gisslinger H et al Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998; 92: 802-809.
16. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ et al. in multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003; 101: 1520-1529.
17. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 1996; 93: 13931-13936.
18. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175-187.
19. Fonseca R, Harrington D, Oken M, Kyle R, Dewald G, Bailey R et al. Myeloma and the t(11;14)(q13;q32) represents a uniquely defined biological subset of patients. Blood 2002; 99: 3735-3741.
20. Debes-Marun C, Dewald G, Bryant S, Picken E, Santana-Dávila S, Gonzalez-Paz N et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003; 17: 427-436.
21. Fonseca R, Debes-Marun C, Picken E, Dewald G, Bryant S, Winkler J et al. The recurrent IgH translocations are highly associated with non-hyperdiploid variant multiple myeloma. Blood. (Prepublished online June 12, 2003; doi: 10.1182/blood-2003-02-0493).
22. Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurtin PJ. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol 2000; 113: 831-837.
23. Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA et al. Plasmablastic morphology - an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 1998; 91: 2501-2507.
24. Fonseca R, Oken M, Greipp P. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathies of undetermined significance. Blood 2001; 98: 1271-1272.